All Blogs
Dec 05, 2024
FDA Approves Zimmer Biomet’s Oxford® Cementless Partial Knee; ReCerf® Sets Milestone as First All-Ceramic Hip Resurfacing Approved Worldwide; Orthocell Achieves US FDA 510(k) Clearance Milestone for Remplir Regulatory Study; Hologic’s Research Shows AI Breast Imaging Maintains Performance Across All Demographics; GE HealthCare Expands MRI Capabilities with Sonic DL’s Advanced Deep Learning; Terumo Unveils the R2P NaviCross Peripheral Support Catheter
Zimmer Biomet Received FDA Approval for Oxford® Cementless Partial Knee, the Only Cementless Partial Knee Replacement Implant in the U.S. On November 25, 2024, Zimmer Biomet Holdings, Inc., a global leader in medical technology, announced that its Oxford® Cementless Partial Knee received Premarket Approval...
Read More...
Dec 04, 2024
Biochips in Healthcare: 8 Groundbreaking Applications Shaping the Industry
Biochips, small devices that integrate biological materials and electronic components, have revolutionized healthcare by enabling rapid, precise, and cost-effective diagnostic and therapeutic solutions. These microdevices combine microfluidics, biosensors, and nanotechnology to analyze and manipulate biological inf...
Read More...
Dec 03, 2024
FDA Grants Fast Track for Lin BioScience’s LBS-007; Alnylam’s AMVUTTRA sNDA Under Review; FDA Approves RAPIBLYK for Atrial Fibrillation; Applied Therapeutics Receives CRL for Govorestat in Galactosemia; R289 Gets Fast Track for Lower-Risk MDS.
Lin BioScience Receives FDA Fast Track Designation for LBS-007 Lin BioScience, a clinical-stage biopharmaceutical company focused on developing innovative therapies for acute leukemia, announced that its lead pipeline candidate, LBS-007, has been granted Fast Track Designation by the FDA for the treatment of acu...
Read More...
Dec 02, 2024
Celiac Disease Treatment: Who Will Secure First-Mover Advantage?
Celiac disease is considered a serious autoimmune disease, which is estimated to affect 1 in 100 people worldwide. Moreover, 2.5 million Americans are undiagnosed and are at risk for long-term health complications. As per secondary, commonly known clinical types of celiac disease include Classical, Non-cla...
Read More...
Nov 29, 2024
From Beta to Alpha Emitters: Radioligand Therapies Reshaping the Neuroendocrine Tumors Treatment Landscape
Radioligand therapies are rapidly transforming the neuroendocrine tumor treatment landscape, offering new hope to patients and reshaping the market dynamics. This innovative approach, which combines the precision of targeted therapy with the potency of radiation, is gaining significant traction in the oncology comm...
Read More...
Nov 28, 2024
FDA Clears Medtronic’s New Inpen™ App; Zimmer Biomet Gets FDA Approval for Oxford® Cementless Partial Knee; Perimeter B-Series OCT with ImgAssist AI 2.0 Shows Significant Superiority Over Standard-of-Care in Pivotal Clinical Trial; Edwards’ SAPIEN 3 Ultra RESILIA Valve Maintains Exceptional Patient Outcomes in Real-World Settings; Abbott Introduces AVEIR™ VR Leadless Pacemaker System to Indian Market; GE HealthCare’s Pristina Via Transforms Mammography with Improved Workflow and Patient Care
Medtronic Received FDA Clearance for the New Inpen™ App, Paving the Way for its Smart MDI System Launch with Simplera™ CGM On November 20, 2024, Medtronic, a global leader in healthcare technology, announced the U.S. Food and Drug Administration (FDA) clearance for its new InPen™ app, which includes advanc...
Read More...
Nov 27, 2024
AI in Cancer Diagnostics: Paving the Way for Early Detection and Precision Treatment
Artificial Intelligence (AI) is revolutionizing numerous fields, and healthcare, particularly cancer diagnostics, is no exception. With the promise of faster, more accurate diagnoses, AI is transforming how clinicians detect, diagnose, and treat cancer. By leveraging vast amounts of medical data, advanced algorithm...
Read More...
Nov 26, 2024
FDA Grants Orphan Drug Designation for Ractigen’s RAG-21 in ALS; Intellia’s Nexiguran RMAT for ATTR Amyloidosis; FDA Approves Acoramidis for ATTR-CM; Jazz Wins FDA Approval for Ziihera in HER2-Positive Biliary Cancer; J&J Seeks FDA Approval for Subcutaneous TREMFYA in Colitis
Ractigen Therapeutics Receives FDA Orphan Drug Designation for RAG-21 to Treat ALS Ractigen Therapeutics has announced that the FDA has granted Orphan Drug Designation (ODD) to RAG-21, its novel siRNA therapy for treating amyotrophic lateral sclerosis (ALS). RAG-21 specifically targets FUS-ALS, one of the most a...
Read More...
Nov 25, 2024
5 Emerging Cell and Gene Therapies That Could Revolutionize Parkinson’s Disease Treatment
Cell and gene therapies are transforming Parkinson's treatment, bringing new hope to patients who previously had few options. While traditional approaches focus on symptom management, these advanced therapies target the underlying causes of the disease. By introducing healthy cells or repairing faulty genes, resear...
Read More...
Nov 21, 2024
Cartessa Aesthetics teams with Classys for Everesse; LogicMark unveils Freedom Alert Max; GE HealthCare clears SIGNA MAGNUS MRI; OMRON’s BP monitor with AI-powered AFib detection gets FDA approval; Boston Scientific’s WATCHMAN FLX™ cuts bleeding risk; Encora Therapeutics wraps ULTRE trial for tremor device
Cartessa Aesthetics Partnered With Classys, Inc. to Bring Everesse to the US Market On November 14, 2024, Cartessa Aesthetics, a leading North American aesthetic medical device company, collaborated with Classys, Inc., a prominent global aesthetics firm based in South Korea, to introduce EVERESSE by Volnew...
Read More...